Tranexamic acid 4-(Aminomethyl)cyclohexanecarboxylic acid Tranexamic Acid Powder
1. Product advantages
High purity, all above 98.5%, no impurities after dissolution
We will test each batch to ensure quality
OEM and private brand services designed for free
Various cap colors available
We can also provide MT1 peptide powder
2. Factory advantages
Professional research team
More than 5 doctors in high-tech R&D laboratories
More than 1000 m2 of factory production line to ensure stable supply
More than 1200 factories to manufacture products and control quality
3. Service advantages
24-hour online service
Track package information and update it for customers
Professional sales team
Accept small order service
Redelivery service if detained by customs
Product Introduction:
Item | Specification | Result |
Description | White powder | Conform |
Identification | IR test | Conform |
PH | 7.0~8.0 | 7.4 |
Related substances Liquid chromatography |
ImpurityA ≤0.1% ImpurityB≤0.2% Any other impurity≤0.1% All other impurity≤0.2% |
<0.1% <0.2% <0.1% <0.2% |
Loss on drying | ≤0.5% | 0.3% |
Residue on ignition | ≤0.1% | <.08% |
Heavy metals | ≤10ppm | <10ppm |
Chlorides | ≤14ppm | <140ppm |
Sulphated ash | ≤0.1% | <0.1% |
Assay | 99.0%~101.0% | 99.76% |
In addition to stabilizing fibrin, 4-(aminomyl) cyclohexanocarboxylic acid can also inhibit the degradation of protein into vasoactive peptides, and ultimately reduce the permeability of capillaries and increase its resistance to vascular fragility. In addition, tranatemic acid can also achieve anti-allergic and anti-inflammatory effects by inhibiting the production of coagulin and other active peptides that can cause vascular permeability enhancement, allergic reaction and inflammatory lesions, and can also increase collagen synthesis in fibrin clots, thereby increasing the strength and stability of clots and reducing bleeding.
Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures.
Tranexamic acid has been found to decrease the risk of death in people who have significant bleeding due to trauma. However, it
may actually increase the risk of death due to bleeding if administered more than 3 hours after the injury.
CAS NO:27813-02-1
CAS NO:2113-05-5
CAS NO:57-85-2
CAS NO:49851-31-2
CAS NO:102-97-6
CAS NO:315-30-0
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View